Habte A. Yimer - Texas Oncology - Tyler

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 73 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

P-414 Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with a Selinexor-Containing Triplet-Based Regimen

Andrew Whiteley, Stephen Ijioma, David Ray,Spencer Langerman, Ellen Hu,Amy Pierre,Tomer Mark,Habte Yimer

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2024): S273-S274

引用0浏览0引用

ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First-Line (1L) Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) after Response to Standard Therapy

Jason Westin, John Burke,Ryan Lynch,Jeremy Abramson,Don Stevens,Matthew Matasar,Lindsey Fitzgerald, Alan Zausner Skarbnik,Chaitanya Iragavarapu,James Essell,Bradley Hunter,Akil Merchant,Indumathy Varadarajan,Anand Tandra,Edward Licitra,Locke Bryan,Rushang D. Patel, Rajesh Behl, Jeff Sharmann, Houston E. Holmes,Suzanne Fanning,Habte Yimer,Mitul Gandhi,Gary Simmons,Amy Feng,Lynn Navale, Srinivas Ghatta, John B. Le Gall, Alex F. Herrera

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2024): S602-S603

引用0浏览0引用

OUTREACH: Phase 2 Study of Lisocabtagene Maraleucel As Outpatient or Inpatient Treatment at Community Sites for R/R LBCL

Blood advancesno. 23 (2024): 6114-6126

引用0浏览0WOS引用

Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy,Benjamin B. Freeman, Ben Zhang,John M. Burke,Jennifer L. Cultrera,Habte A. Yimer, Edwin C. Kingsley,Charles M. Farber,James D'Olimpio, Hui Yao,Adam Idoine, Qi An, Jeff P. Sharman

Bloodno. Supplement 1 (2024): 4632-4632

引用0浏览0引用

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Jason R. Westin, Alex F. Herrera,Ryan Lynch, Jeremy S. Abramson,Don A. Stevens, Matthew Matasar, Lindsey Fitzgerald, Alan P Skarbnik,Chaitanya Iragavarapu,James H Essell,Bradley D. Hunter,Akil Merchant, Indumathy Varadarajan,Anand Tandra, Edward Licitra,Locke Johnson Bryan,Rushang D. Patel, Rajesh Behl, Jeff P. Sharman,Houston Holmes,Habte A. Yimer,Mitul Gandhi, Nosha Farhadfar, Nancy L. Bartlett, Michael Leukam,Tahir Latif,Paolo Caimi,Jean Yared,Amy Feng,Lynn Navale, Sri Ghatta, John B. Le Gall, Zachary J Roberts,John M. Burke

Bloodno. Supplement 1 (2024): 3132.1-3132.1

引用0浏览0引用

CT-412 ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First-Line (1L) Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) after Response to Standard Therapy

Jason Westin, John Burke,Ryan Lynch,Jeremy Abramson,Don Stevens,Matthew Matasar,Lindsey Fitzgerald, Alan Zausner Skarbnik,Chaitanya Iragavarapu,James Essell,Bradley Hunter,Akil Merchant,Indumathy Varadarajan, Anand Rotte,Edward Licitra,Locke Bryan,Rushang D. Patel, Rajesh Behl, Jeff Sharmann, Houston E. Holmes,Suzanne Fanning,Habte Yimer,Mitul Gandhi,Gary Simmons,Amy Feng,Lynn Navale, Srinivas Ghatta, John B. Le Gall, Alex F. Herrera

Clinical Lymphoma Myeloma and Leukemia (2024)

引用0浏览0引用

A Phase 3b Study of Venetoclax and Azacitidine or Decitabine in an Outpatient Setting in Patients with Acute Myeloid Leukemia

Sudhir Manda,Bertrand M. Anz III,Christopher Benton,E. Randolph Broun,Habte A. Yimer,John S. Renshaw, George Geils Jr,Jesus Berdeja, Jose Cruz,Jason M. Melear,Suzanne Fanning, Luke Fletcher,Yukun Li,Yinghui Duan,Michael E. Werner,Jalaja Potluri, Madhavi V. Pai,William B. Donnellan

HEMATOLOGICAL ONCOLOGYno. 3 (2024)

引用0浏览0WOS引用

Multi-cancer Early Detection Test Sensitivity for Cancers with and Without Current Population-Level Screening Options

Spencer H. Shao,Brian Allen,Jessica Clement,Gina Chung,Jingjing Gao,Earl Hubbell,Minetta C. Liu,Charles Swanton,W. H. Wilson Tang,Habte Yimer,Mohan Tummala

TUMORI JOURNALno. 3 (2023): 335-341

引用0浏览0WOS引用

MM-465 In-Class Transition (ict) from Parenteral Bortezomib-Based Induction to All-Oral Ixazomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Subgroup Analysis from the Community-Based US MM-6 Study

Saulius K. Girnius,Joshua Richter,Roger Lyons,Kimberly Bogard,Sudhir Manda,Ruemu E. Birhiray,Habte A. Yimer,Kim Tran,Suman Kambhampati,Jyoti Arora,Stephen J. Noga,Robert M. Rifkin

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023): S501-S501

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn